| |
|
|
|
|
|
 |
| |
|
¶ó¹Ì½Ç¿ø½º¿Ü¿ë¾× LAMISIL ONCE
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
653600240
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
[ºñ±Þ¿©]
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸í-¿¯Àº Ȳ»öÀ¸·Î ¿¡Åº¿ÃÀÇ Æ¯ÀÌÇÑ ³¿»õ°¡ ÀÖ´Â ¿Ü¿ë¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
4g X 1°³ |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 4±×·¥ |
1 °³ |
Æ©ºê |
8806536002400 |
8806536002417 |
|
|
| ÁÖ¼ººÐÄÚµå |
235702CLQ
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
Trichophyton (T. rubrum, T. mentagrophytes, T.verrucosum, T. violaceum), Microsporum canis ¹× Epidermophyton floccosum °ú °°Àº ÇǺλç»ó±Õ¿¡ ÀÇÇÑ ÇǺΰ¨¿°Áõ : Á·ºÎ¹é¼±(¹ß¹é¼±Áõ,¹«Á»)(15¼¼ ÀÌ»óÀÇ Ã»¼Ò³â ¹× ¼ºÀο¡ ÇÑÇÔ)
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
ÀÌ ¾àÀº ´Ü 1ȸ Àû¿ëÇÑ´Ù.
Àû¿ë Àü¿¡ ¾çÂÊ ¹ß°ú ¾çÂÊ ¼ÕÀ» ±ú²ýÀÌ ¾Ä°í, ¿ÏÀüÈ÷ °ÇÁ¶½ÃŲ ÈÄ È¯ºÎ(ÁúȯºÎÀ§)¿Í ±× ÁÖÀ§°¡ ÃæºÐÈ÷ Àû¼ÅÁöµµ·Ï ÃæºÐÇÑ ¾çÀ» ¹Ù¸¥´Ù.
Áø±Õ(°õÆÎÀÌ)ÀÇ ¿Ïº®ÇÑ Ä¡·á¸¦ À§Çؼ´Â º´¼Ò(¾ÆÇºÎÀ§)°¡ ³ªÅ¸³ªÁö ¾ÊÀº ÂÊ ¹ßÀ̶ó ÇÒÁö¶óµµ, ¾çÂÊ ¹ß ¸ðµÎ¿¡ Àû¿ëÇÑ´Ù. ÀÌ ¾àÀ» ¹ß°¡¶ô »çÀÌ ¸ðµÎ ¾ã°Ô Æì ¹Ù¸£°í ¹ß¹Ù´Ú Àüü¿Í ¹ß¹Ù´ÚÀ¸·ÎºÎÅÍ ¾à 1.5cm ³ôÀ̱îÁö ÀÌ ¾àÀ» Àû¿ëÇϸç Çʸ§ÀÌ µÉ ¶§±îÁö 1~2ºÐ°£ °ÇÁ¶½ÃŲ´Ù. ±× ÈÄ ¼ÕÀ» ±ú²ýÀÌ ¾Ä´Â´Ù. ÀÌ ¾à Àû¿ë ½Ã¿¡´Â ¹®Áú·¯ ¹Ù¸£Áö ¾Ê´Â´Ù.
ÀÌ ¾àÀÇ È¿°ú¸¦ ³ôÀÌ·Á¸é Àû¿ë ÈÄ 24½Ã°£ µ¿¾È ¾ÄÁö ¾Ê°í ±×´ë·Î µÐ´Ù. µû¶ó¼ ÀÌ ¾àÀº »þ¿ö ¶Ç´Â ¸ñ¿å ÈÄ¿¡ ¹Ù¸£±â¸¦ ±ÇÀåÇÏ°í ±× ´ÙÀ½³¯ÀÇ °°Àº ½Ã°£ ±îÁö ±â´Ù¸° ÈÄ ¹ßÀ» ´Ù½Ã ¾Ä´Â´Ù.
ȯÀÚ´Â À§ÀÇ »ç¿ë¹ý¿¡ µû¶ó ÇÊ¿äÇÑ ¾ç¸¸Å ¾ç ¹ß¿¡ µµÆ÷ÇÑ´Ù. »ç¿ëÇÏÁö ¾ÊÀº ¾àÀº ¹ö¸°´Ù.
º¸Åë ÀÓ»ó Áõ»óÀÇ ¿ÏÈ´Â ¸îÀÏ ¾È¿¡ ³ªÅ¸³´Ù.
¸¸¾à 1ÁÖ°¡ Áö³ ÈÄ¿¡µµ °³¼±ÀÇ Â¡Èİ¡ º¸ÀÌÁö ¾ÊÀ¸¸é, ÀÇ»ç¿Í »ó´ãÇÑ´Ù. ÀÌ ¾àÀ¸·Î ¹Ýº¹ Ä¡·áÇÑ °æ¿ìÀÇ µ¥ÀÌÅÍ´Â ¾ø´Ù. µû¶ó¼ Ä¡·á ÁßÀÎ Á·ºÎ¹é¼±(¹ß¹é¼±Áõ,¹«Á»)ÀÇ ÀÌÂ÷ Ä¡·á¿¡ ÃßõµÇÁö ¾Ê´Â´Ù.
|
| ±Ý±â |
´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» º¹¿ë(»ç¿ë)ÇÏÁö ¸» °Í.
1) Å׸£ºñ³ªÇÉ ¹× ÀÌ ¾à ¼ººÐ¿¡ °ú¹ÎÁõ ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ
2) ÀӺΠ¶Ç´Â ÀÓ½ÅÇϰí ÀÖÀ» °¡´É¼ºÀÌ ÀÖ´Â ¿©¼º ¹× ¼öÀ¯ºÎ
3) ¼Ò¾Æ(15¼¼ ¹Ì¸¸)
|
| ½ÅÁßÅõ¿© |
´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» º¹¿ë(»ç¿ë)Çϱâ Àü¿¡ ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í
1) ÀÓºÎ
ÀӺο¡ ´ëÇÑ Å׸£ºñ³ªÇÉÀÇ ÀÓ»ó °æÇèÀº ¾ø´Ù.
ÀÌ ¾àÀÇ µ¿¹° ½ÇÇè¿¡¼ ±âÇüÀ¯¹ß ¶Ç´Â ¹èÅÂÀÚµ¶¼ºÀÇ °¡´É¼ºÀº ³ªÅ¸³ªÁö ¾Ê¾Ò´Ù.
2) ¼öÀ¯ºÎ
Å׸£ºñ³ªÇÉÀº ¸ðÀ¯ Áß¿¡ ºÐºñµÇ¹Ç·Î, ¼öÀ¯ÇÏ´Â µ¿¾È ÀÌ ¾àÀ» »ç¿ëÇØ¼´Â ¾ÈµÈ´Ù.
3) ¼öÅ´É
µ¿¹° ½ÃÇè¿¡¼ Å׸£ºñ³ªÇÉÀÇ ¼öÅ´ɿ¡ ´ëÇÑ ¿µÇâÀº ¾ø¾ú´Ù.
4) ¼Ò¾Æ
ÀÌ ¾àÀº 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡ ´ëÇØ ¾ÈÀü¼º ¹× À¯È¿¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾ÊÀ¸¹Ç·Î ÀÌ ¾àÀ» 15¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ¿¡ Åõ¿©ÇÏÁö ¾Ê´Â´Ù(¼Ò¾Æ¿¡ ´ëÇÑ »ç¿ë°æÇèÀÌ Àû´Ù.)
5) ³ëÀÎ
³ëÀΠȯÀÚ¿¡°Ô ´Ù¸¥ ¿ë·®ÀÌ ¿ä±¸µÇ°Å³ª ÀþÀº ȯÀÚ¿Í ´Ù¸¥ ÀÌ»ó¹ÝÀÀ °æÇè¿¡ ´ëÇÑ Áõ°Å´Â ¾ø´Ù.
6) ¾ËÄÚ¿ÃÀÌ ÀÚ±ØÇÒ ¼ö ÀÖ´Â º´º¯(º´¿¡ ÀÇÇÑ ¸öÀÇ º¯È)ÀÌ Àִ ȯÀÚ¿¡°Ô »ç¿ë ½Ã ÁÖÀÇÇØ¾ß ÇÑ´Ù.
|
| ÀÌ»ó¹ÝÀÀ |
.´ÙÀ½°ú °°Àº »ç¶÷Àº ÀÌ ¾àÀ» º¹¿ë(»ç¿ë)À» Áï°¢ ÁßÁöÇϰí ÀÇ»ç, Ä¡°úÀÇ»ç, ¾à»ç¿Í »óÀÇÇÒ °Í. »ó´ã½Ã °¡´ÉÇÑÇÑ ÀÌ Ã·ºÎ¹®¼¸¦ ¼ÒÁöÇÒ °Í
1) °úµµÇÑ ÀÚ±ØÀÌ ³ªÅ¸³ª°Å³ª ´õ ½ÉÇØÁö¸é Åõ¿©¸¦ ÁßÁöÇϰí ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »óÀÇÇÑ´Ù.
2) ÀÌ»ó¹ÝÀÀÀº Àû¿ë ºÎÀ§¿¡ °¡º±°í ÀϽÃÀûÀÎ ¹ÝÀÀÀ» Æ÷ÇÔÇÑ´Ù. ¸Å¿ì µå¹® ¿¹·Î, ¾Ë·¯Áö ¹ÝÀÀÀÌ ÀϾ ¼ö ÀÖ´Ù.
3) ¾Æ·¡¿¡ ÀÌ»ó¹ÝÀÀ ¸ñ·ÏÀº ±â°ü°è ºÐ·ù¿Í ºóµµ¸¦ ±âÁØÀ¸·Î ÇÑ´Ù.
ºóµµ : ¸Å¿ì ÈçÇϰÔ(¡Ã 1/10), ÈçÇϰÔ(¡Ã 1/100, < 1/10), ÈçÇÏÁö ¾Ê°Ô(¡Ã 1/1,000, < 1/100), µå¹°°Ô(¡Ã 1/10,000, <1/1,000), ¸Å¿ì µå¹°°Ô(< 1/10,000), ¾Ë·ÁÁöÁö ¾ÊÀ½(ÀÌ¿ë °¡´É ÀÚ·á¿¡¼ Æò°¡ ºÒ°¡), °¢ ºóµµ ±×·ì ³»¿¡¼, ÀÌ»ó¹ÝÀÀÀº ½É°¢¼ºÀÌ °¨¼ÒÇÏ´Â ¼ø¼·Î ±â¼úµÇ¾î ÀÖ´Ù.
ÇǺΠ¹× ÇÇÇÏ(ÇǺιØ) Á¶Á÷ Àå¾Ö
¸Å¿ì µå¹°°Ô : ¹ßÁø, °¡·Á¿ò, ¹°ÁýÇǺο° ¹× µÎµå·¯±â¿Í °°Àº ¾Ë·¯Áö ¹ÝÀÀ
Àü½ÅÀå¾Ö ¹× Àû¿ëºÎÀ§ »óÅÂ
ÈçÇÏÁö ¾Ê°Ô : ÇǺΠ°ÇÁ¶ÇÔ, ÇǺΠÀÚ±Ø ¶Ç´Â ÀÛ¿°¨(Ȳö°¨)°ú °°Àº Àû¿ë ºÎÀ§ ¹ÝÀÀ
|
| Related FDA Approved Drug |
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Bµî±Þ
(terbinafine; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
ÀÓ»êºÎ ¶Ç´Â ÀӽŰèȹÁß º¹¿ë±ÝÁö |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Terbinafine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Terbinafine is hypothesized to act by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes.
|
| Pharmacology |
Terbinafine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Terbinafine is an allylamine antifungal agent and acts by inhibiting squalene epoxidase, thus blocking the biosynthesis of ergosterol, an essential component of fungal cell membranes. in vitro, mammalian squalene epoxidase is only inhibited at higher (4000 fold) concentrations than is needed for inhibition of the dermatophyte enzyme. Depending on the concentration of the drug and the fungal species test in vitro, Terbinafine may be fungicidal. However, the clinical significance of in vitro data is unknown.
|
| Metabolism |
Terbinafine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2D6 (CYP2D6)
|
| Absorption |
Terbinafine¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed from gastrointestinal tract.
|
| Toxicity |
Terbinafine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Terbinafine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Terbinafine¿¡ ´ëÇÑ Description Á¤º¸ Terbinafine hydrochloride (Lamisil) is a synthetic allylamine antifungal. It is highly lipophilic in nature and tends to accumulate in skin, nails, and fatty tissues. Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene epoxidase, an enzyme that is part of the fungal cell wall synthesis pathway.
|
| Dosage Form |
Terbinafine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Cream TopicalSpray TopicalTablet Oral
|
| Drug Category |
Terbinafine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AllylaminesAntifungal AgentsAntifungalsEnzyme InhibitorsTrypanocidal Agents
|
| Smiles String Canonical |
Terbinafine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN(CC=CC
|
| Smiles String Isomeric |
Terbinafine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN(C\C=C\C
|
| InChI Identifier |
Terbinafine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3
|
| Chemical IUPAC Name |
Terbinafine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2020-08-13
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|